Aquestive Therapeutics, a pharmaceutical company advancing medicines to improve current standards of care, has expanded its exclusive license and supply agreement with Atnahs Pharma UK Ltd., a global pharmaceutical company that works to extend and expand the lifecycle of established medicines, for Libervant (diazepam) Buccal Film to cover the rest of the world, excluding the U.S, Canada, and China.

The original licensing agreement with Pharmanovia announced in Sept. 2022 covered the European Union, United Kingdom, Sweden, Switzerland, and Norway, as well as countries in the Middle East and North Africa (MENA).

“We are pleased to announce the expansion of our collaboration with Pharmanovia,” said Daniel Barber, CEO of Aquestive. “We believe Pharmanovia’s experience and geographic footprint align well with our goal of providing patients throughout the world with access to Libervant. This announcement also aligns with our mission to put the patient at the center of everything we do. We will continue to advocate for patient access, patient choice, and patient empowerment on a global basis.”

Pharmanovia CEO, James Burt, said, “Following a strong start to our collaboration with Aquestive Therapeutics, we’ve expanded our agreement to include many more territories. Our experience with diazepam marketed under an established brand in Valium, combined with Aquestive Therapeutics’ unique PharmFilm technology, provides a potentially significant delivery option to caregivers and patients in times of critical need and enables us to optimize an existing medicine to better meet the needs of patients, healthcare professionals and payors.”

Pursuant to the expanded agreement, Aquestive Therapeutics will serve as the exclusive sole manufacturer and supplier for the product and Pharmanovia will be responsible for all regulatory and commercialization activities. Aquestive will receive an undisclosed upfront payment and, if approved for market access, milestone payments, and double-digit royalties on net sales of the diazepam buccal film in the licensed territories.